| 发明名称 | Induction of IL-12 using immunotherapy | ||
| 摘要 | The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity. | ||
| 申请公布号 | US9233156(B2) | 申请公布日期 | 2016.01.12 |
| 申请号 | US201213581745 | 申请日期 | 2012.05.02 |
| 申请人 | IMMUNOVATIVE THERAPIES LTD. | 发明人 | Har-Noy Michael |
| 分类号 | A61K38/20;A61K39/44;A61K39/385;A61K39/39;A61K39/00 | 主分类号 | A61K38/20 |
| 代理机构 | Westman, Champlin & Koehler, P.A. | 代理人 | Westman, Champlin & Koehler, P.A. ;Sawicki Z. Peter;Goswitz Visala |
| 主权项 | 1. A method of treating a patient with a solid tumor, the method comprising: inducing the production of endogenous IL-12 in the patient, wherein the endogenous IL-12 is induced by administering a composition comprising activated allogeneic Th1 cells to the patient, wherein the Th1 cells are activated by cross-linking CD3 and CD28, wherein administration of the composition increases the level of IFN-gamma and the Th1 response in the patient; measuring the plasma level of endogenous IL-12 in the patient; and readministering the composition until endogenous IL-12 in the plasma of the patient is at least about 5000 pg/ml. | ||
| 地址 | Jerusalem IL | ||